38701714|t|Lead optimization based design, synthesis, and pharmacological evaluation of quinazoline derivatives as multi-targeting agents for Alzheimer's disease treatment.
38701714|a|The complexity and multifaceted nature of Alzheimer's disease (AD) have driven us to further explore quinazoline scaffolds as multi-targeting agents for AD treatment. The lead optimization strategy was utilized in designing of new series of derivatives (AK-1 to AK-14) followed by synthesis, characterization, and pharmacological evaluation against human cholinesterase's (hChE) and beta-secretase (hBACE-1) enzymes. Amongst them, compounds AK-1, AK-2, and AK-3 showed good and significant inhibitory activity against both hAChE and hBACE-1 enzymes with favorable permeation across the blood-brain barrier. The most active compound AK-2 revealed significant propidium iodide (PI) displacement from the AChE-PAS region and was non-neurotoxic against SH-SY5Y cell lines. The lead molecule (AK-2) also showed Abeta aggregation inhibition in a self- and AChE-induced Abeta aggregation, Thioflavin-T assay. Further, compound AK-2 significantly ameliorated Abeta-induced cognitive deficits in the Abeta-induced Morris water maze rat model and demonstrated a significant rescue in eye phenotype in the A -phenotypic drosophila model of AD. Ex-vivo immunohistochemistry (IHC) analysis on hippocampal rat brains showed reduced Abeta and BACE-1 protein levels. Compound AK-2 suggested good oral absorption via pharmacokinetic studies and displayed a good and stable ligand-protein interaction in in-silico molecular modeling analysis. Thus, the compound AK-2 can be regarded as a lead molecule and should be investigated further for the treatment of AD.
38701714	77	88	quinazoline	Chemical	MESH:D011799
38701714	131	150	Alzheimer's disease	Disease	MESH:D000544
38701714	204	223	Alzheimer's disease	Disease	MESH:D000544
38701714	225	227	AD	Disease	MESH:D000544
38701714	263	274	quinazoline	Chemical	MESH:D011799
38701714	315	317	AD	Disease	MESH:D000544
38701714	416	420	AK-1	Gene	203
38701714	424	429	AK-14	Chemical	-
38701714	511	516	human	Species	9606
38701714	517	531	cholinesterase	Gene	590
38701714	603	607	AK-1	Gene	203
38701714	609	613	AK-2	Gene	204
38701714	619	623	AK-3	Gene	50808
38701714	794	798	AK-2	Gene	204
38701714	820	836	propidium iodide	Chemical	MESH:D011419
38701714	838	840	PI	Chemical	MESH:D011419
38701714	864	868	AChE	Gene	43
38701714	892	902	neurotoxic	Disease	MESH:D020258
38701714	911	918	SH-SY5Y	CellLine	CVCL:0019
38701714	950	954	AK-2	Gene	204
38701714	968	973	Abeta	Gene	54226
38701714	1012	1016	AChE	Gene	43
38701714	1025	1030	Abeta	Gene	351
38701714	1044	1056	Thioflavin-T	Chemical	MESH:C009462
38701714	1082	1086	AK-2	Gene	204
38701714	1113	1118	Abeta	Gene	54226
38701714	1127	1145	cognitive deficits	Disease	MESH:D003072
38701714	1153	1158	Abeta	Gene	54226
38701714	1185	1188	rat	Species	10116
38701714	1291	1293	AD	Disease	MESH:D000544
38701714	1354	1357	rat	Species	10116
38701714	1380	1385	Abeta	Gene	54226
38701714	1390	1396	BACE-1	Gene	29392
38701714	1422	1426	AK-2	Gene	204
38701714	1606	1610	AK-2	Gene	204
38701714	1702	1704	AD	Disease	MESH:D000544
38701714	Negative_Correlation	MESH:D011799	MESH:D000544
38701714	Association	204	43
38701714	Positive_Correlation	MESH:D003072	54226
38701714	Negative_Correlation	204	54226
38701714	Association	MESH:D011419	43
38701714	Positive_Correlation	351	43
38701714	Association	MESH:D011419	204
38701714	Association	MESH:D000544	204
38701714	Negative_Correlation	204	29392
38701714	Negative_Correlation	MESH:D003072	204
38701714	Negative_Correlation	204	351

